Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Biohacking | Biohacking |
| Evidence strength | Early-stage evidence | Early-stage evidence |
| Evidence Score | 1/5 | 2/5 |
| User rating | 3.3 (21) | 4.3 (58) |
| Typical dose | In Russian clinical practice (Phenotropil): usually 100–200 mg once daily in the morning; dosing in informal, uncontrolled sources varies more widely, with no clearly established, safe upper limit confirmed by studies in healthy humans | Exclusively within approved clinical trials: a single 25 mg dose (the "therapeutic" dose in the COMPASS Pathways trial) or a two-session protocol of 20–30 mg in the Johns Hopkins trial, each time under the direct supervision of two trained therapists in a clinical office. |
| Form | Tablets (Russian pharmaceutical preparation) or powder/capsules sold as a 'research chemical' outside Russia, without external quality control | Synthetic, standardized psilocybin in capsule form — not natural mushrooms with variable, unpredictable active-substance content. |
| Average price | Jako "research chemical": ok. 70–140 zł za opakowanie starczające na miesiąc, zależnie od źródła i braku standaryzacji | — |
| Monthly cost | ok. 70–140 zł/miesiąc, przy czym cena nie odzwierciedla kontrolowanej jakości ani legalności produktu | — |
| Time to effects | Subjective stimulant effects are sometimes reported within hours of taking a dose in informal user accounts, but no controlled study in healthy, adult humans has confirmed a clear time course or the actual magnitude of any effect. | Subjective, acute psychedelic effects appear 20–40 minutes after dosing and last 4–6 hours. The antidepressant effect, if it occurs, tends to be noticeable within days of the session, and in the COMPASS Pathways trial was still partially measured at 12 weeks — though in some patients it faded over time and required consideration of another session or a return to standard treatment. |
| Who it's for | There's no well-established target group in Western markets, where the substance isn't an approved drug or legal supplement | Exclusively participants in approved clinical trials on treatment-resistant depression, qualified after detailed psychiatric assessment |